http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105061397-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
filingDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2018-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-105061397-B |
titleOfInvention | A kind of c-type crystal formation of Ceritinib and preparation method and application |
abstract | The invention provides a kind of c-type crystal formation of Ceritinib.There is characteristic peak at 2 θ angles is 4.9 °, 9.4 °, 9.9 °, 12.2 °, 13.7 °, 14.2 °, 14.4 °, 14.9 °, 15.6 °, 16.5 °, 17.0 °, 17.7 °, 18.9 °, 20.6 °, 22.0 °, 25.0 °, 26.6 °, 25.9 ° and 28.5 ° in the X ray powder diffraction patterns that the c-type crystal formation of the Ceritinib is obtained using Cu K alpha ray measurements.The present invention also provides the preparation method and application of the c-type crystal formation of above-mentioned Ceritinib.The c-type crystal formation crystallinity of the Ceritinib of the present invention is high, water solubility is high, and its preparation method is simple, is easily controlled, and c-type crystal formation, and favorable reproducibility is easily prepared, and significantly improve the oral administration biaavailability of Ceritinib. |
priorityDate | 2015-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.